José Alexandre Ferreira earned a PhD in Biochemistry in 2010 through a joint program between the University of Aveiro and the University of Guelph (Canada), focusing on gastric cancer vaccines using Helicobacter pylori polysaccharides. He conducted postdoctoral research at the University of Aveiro’s Mass Spectrometry Center on protein glycosylation in cancer. Since 2012, he has led a research team at the Portuguese Institute of Oncology of Porto (IPO-Porto) in translational cancer glycobiology and glycotherapies. From 2016–2019, he was affiliated with i3S (University of Porto) and the International Iberian Nanotechnology Laboratory. Dr. Ferreira supervises MSc, PhD, and postdoctoral researchers and consults for national and European funding agencies. He is Principal Researcher at IPO-Porto and CEO and co-founder of GlycoMatters. He frequently lectures on glycobiology, glycochemistry, and oncology and is an author of numerous publications and patents.